



HIV-2 and its neurological
manifestations
M. Rolfe
The human immunodeficiency virus type 2 (HIV-2)
produces a similar spectrum of illness as HIV-1, including
AIDS, and is clinically indistinguishable. There is evidence
that it is less pathogenic, with a longer natural history. HIV-
2 infection is endemic in West Africa, especially in the
former Portuguese and French colonies. Trade, migration,
war and tourism have been important factors in the spread
of the virus through the subregion and beyond.
Diagnostic facilities necessary for the accurate
diagnosis of neurological disease are not available in most
of Africa and autopsy reports have been few. These
constraints have restricted the information available on the
pattern of neuropathology induced by HIV-2. However, it
possesses neurotropic properties similar to those of HIV-1
and produces disease by means of direct action of the
virus on the nervous system, and immunosuppression
which allows opportunistic infections and tumours to
occur.
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The human immunodeficiency virus type 2 (HIV-2) is the
second human retrovirus that causes acquired immune
deficiency syndrome (AIDS). It was first isolated in 1986 by
Clavel et a/.' from two West African patients with AIDS. This
virus differed antigenically from HIV-1 and was originally
called lymphadenopathy-associated virus type 2 (LAV-2).
They also reported clinical and immunological data on 30
infected patients! mostly from Guinea-Bissau, of whom 17
had AIDS. The new virus was isolated from the peripheral
Iymphocytes of 11 patients and shown to have cytopathic
effects and reverse transcriptase activity. It had a similar
tropism for CD4 T Iymphocytes as HIV-1 but differed
markedly in its envelope glycoprotein which appeared to be
closely related to that of the simian immunodeficiency virus,
the causative agent of an AIDS-like illness in captive
macaques (SIVMAc).3
HIV-2 infection is mainly confined to West Africa,
especially the former Portuguese and French colonies; the
virus has probably been circulating in the region since the
1960s.4 Trade, migration, war and tourism have played
important roles in its spread through the subregion and to
other continents. There is a paucity of accurate information
on the prevalence and distribution of infection in West
African countries because of under-reporting and under-
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diagnosis of disease, and failure to use standardised
methods in epidemiological studies. Nevertheless,
significant levels of infection have been reported from Mali,5
Senegal: The Gambia,' Guinea-Bissau· and Ivory Coast9 in a
variety of sentinel groups. Infection outside West Africa has
been reported but usually in patients connected with the
region. The link with the former Portuguese colonies is
provided by data on HIV-2 infection in Angola,'o,,,
Mozambique" and Brazil." In Europe significant numbers of
patients have been reported from Portugal, France and
Germany, including some cases where there was no West
African association."
HIV-2 is transmitted sexually," by blood or blood
products15 and vertically from mother to child, in the same
manner as HIV-1. There is some suggestion that perinatal
transmission may be less efficient than in HIV-1.'·
There were some early doubts about the pathogenicity of
HIV-2 but it is now accepted that it produces a pattern of
disease similar to that of HIV-1, including AIDS." It may be
less virulent, however, and have a longer natural history. This
concept is supported by evidence of a long latent period in
some patients"·'··,9 and by increasing age-specific
prevalence rates in Guinea~Bissau.'6 A cross-sectional study
of prostitutes in The Gambia showed that HIV-2-infected
subjects had less abnormality of immunological parameters
than those infected with HIV-1.20 HIV-2 isolates show
considerable antigenic variation with varying degrees of
cytopathogenicitY in vitro;" some strains exhibit little or no
cytopathic effects.",23 It is possible that this may be
important with regard to pathogenesis in vivo, but long-term
prospective studies are required.
Clinical manifestations
Infection with HIV-1 or HIV-2 is not clinically distinguishable.
Fevers, weight loss, chronic diarrhoea, lymphadenopathy,
tuberculosis, Kaposi's sarcoma, prurigo and oral candidiasis
are the main presenting features in Africa.
Neurotropism
The propensity of HIV-1 to attack the nervous system is well
known2425 and there is now substantial evidence that HIV-2
exhibits a similar degree of neurotropism.
Brun-Vezinet and colleagues2• in Paris isolated the virus
from the cerebrospinal fluid (CSF) of 2 patients with AIDS or
AIDS-related complex (ARC). Three patients had intrathecal
production of IgG antibodies against HIV-2. Passive transfer
from serum was excluded by the serum/CSF ratio of < 4;
herpes simplex virus antibodies were also absent from the
CSF despite the presence of high titres in serum.
Hugon et a/.2' reported a patient from Ivory Coast who
presented in 1982 with a progressive spastic paraplegia. He
had a normal myelogram and no neurological cause could
be identified at that time. Four years later he was
neurologically stable. HIV-2 antibodies were found by
enzyme-linked immunosorbent assay and Western blot but
HIV-1 and HTLV-1 antibodies were absent.
Klemm et a/.2· described a patient, seropositive for HIV-2,
who developed incontinence, gait disturbance, cognitive
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disfunction and finally spastic paraplegia and peripheral
neuropathy. He had cerebral atrophy on computed
tomography (CT) and magnetic resonance imaging (MRI),
With chronic Inflammation and local production of immune
globulins in the central nervous system.
Molecular biologists isolated a strain of HIV-2 from a
Gambian patient dying solely of neurological disease.29 This
isolate produced higher levels of reverse transcriptase in
fresh human monocytes/macrophages than in cultures of
peripheral Iymphocytes; it was suggested that this ability to
invade macrophages was related to her neurological
disease.
Thus HIV-2, in addition to two other human retroviruses
(HIV-1 and HTLV-1), has neurotropic properties and the
potential to cause neurological disease.
Neurological disease
Investigation of neurological symptoms in Africa is greatly
hampered by the lack of sophisticated technological tools
such as CT and MRI. There are few histopathological reports
on post-mortem findings, and brain biopsies cannot be
undertaken in the majority of countries in West Africa.
Examination of the CSF usually only reveals nonspecific
changes (raised protein levels, increased numbers of
mononuclear cells). These constraints have severely
restricted the information available from Africa and many
patients with neurological disease probably remain
unreported or undiagnosed. They form, however, a
significant proportion of patients with HIV-2 AIDS or ARC; 11
(13%) of 82 patients who died in The Gambia over a 6-year
period had neurological signs and symptoms (unpublished
data).
The effects of HIV-2 on the nervous system may be the
result either of the direct action of the virus itself, or the
consequences of immunosuppression that lead to
opportunistic infections and tumours.
Direct effects of HIV-2
The AIDS dementia complex is a constellation of cognitive,
behavioural and motor abnormalities resulting from direct
retroviral infection of the brain and spinal cord, and has
been extensively reported in HIV-1 infection.30
The majority of patients reported with AIDS dementia
complex due to HIV-2 have been investigated in Europe or
America!",2'29 In an early report on retroviral disease in The
Gambia," 2 out of 11 patients who died of HIV-2 AIDS had
dementia; post-mortem examination of 1 patient showed
cerebral atrophy with dilated ventricles and nonspecific
histological changes (D. C. W. Mabey - personal
communication).
. The only report on post-mortem findings in significant
numbers of HIV-2 AIDS patients was by Lucas and
colleagues.32 Autopsy was perlonmed on 28 (72%) of 39
dying seropositive patients in a general hospital and in a
specialist neurology unit in Abidjan, Ivory Coast; 4 (14%)
had giant cell encephalitis indicative of primary central
nervous system involvement.
Aseptic meningitis33 and myelopathy'" may occur at the
time of seroconversion in HIV-1 infections. The only report of
a primary HIV-2 infection described a similar clinical illness.35
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The spastic paraplegia reported in a patient from Ivory
Coast27 may have represented a primary HIV-2 infection of
the spinal cord.
Opportunistic infections and tumours
These arise as a consequence of the destruction of CD4
Iymphocytes by the virus. In addition there is functional
impairment of macrophages and natural killer cells leading
to suppression of the immune surveillance system. New
infections, especially fungal or viral, may lead to disease as
a consequence of this loss of cell-mediated immunity, or
there may be reactivation of a previous, latent infection.
The protozoon, Toxoplasma gondii, is the most important
cause of opportunistic infection of the central nervous
system. It produces cerebral abscesses, often multiple,
which cause headaches, fits and focal neurological deficits
such as ataxia, hemiplegia and dysphasia. Toxoplasma
antibody levels are not a useful guide in diagnosis although
they are rarely absent in the presence of active disease.3"
There is a typical appearance on CT, with ring-like contrast
enhancement; toxoplasma encephalitis has been diagnosed
in HIV-2-infected patients in Europe".26 and the USA."' In
Africa cerebral toxoplasmosis was found on post-mortem in
4 (14%) patients in Abidjan32 and in 1 patient in The
Gambia."' Involvement of the basal ganglia may lead to
movement disorders;38 1 patient in The Gambia with
hemiballismus responded well to anti-toxoplasma therapy
(P. T. Corrah - personal communication). A parkinsonian
syndrome with tremor, cogwheel rigidity and dyskinesia has
also been observed (C. M. Tang - personal
communication); this patient had HIV-2 antibodies in the
CSF and may have had direct involvement of the
extrapyramidal system with the virus. T. gondii is a common
cause of neurological disease in HIV-2 AIDS patients, and is
frequently undiagnosed in Africa due to lack of facilities; it is
also treatable, so a therapeutic trial of anti-toxoplasma
drugs is warranted in all such patients.
Cryptococcal meningitis is an opportunistic fungal
infection, the initial port of entry of which is the lungs.
Patients with HIV-2 infection and cryptococcal meningitis
have been described in The Gambia," Ivory Coast"2 and the
USA3' but, surprisingly, it does not appear common; no such
patients have been seen in The Gambia in the last 5 years
(P. T. Corrah - personal communication).
Cerebral lymphoma is a rapidly fatal opportunistic B-cell
tumour which requires CT and brain biopsy for diagnosis
during life. It was present in 1 patient in the first reported
series of HIV-2 AIDS patieqts in West Africa,' and in another
at autopsy in Ivory Coast.32
Tuberculosis is the most important opportunistic infection
in Africa, both for HIV-1 and HIV-2 infection.9Tuberculous
meningitis, however, seems relatively uncommon although
post-mortem studies suggest that it may be under-
diagnosed."9
A history of herpes zoster has a strong positive predictive
value (90%) for HIV-1 seropositivity'" in Central Africa. No
studies on HIV-2 infection and herpes zoster have been
reported but this association appears weak in West Africa.
This may be due to the low seroprevalence and reduced
pathogenicity of HIV-2.
The natural history of neurosyphilis has been altered by
HIV-1 infection with an accelerated clinical course, a
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decreased latent period and an increased relapse rate.<1
There is no reported relationship between HIV-2 infection
and neurosyphilis, which again may reflect a lesser degree
of pathogenicity.
There is limited information on cytomegalovirus infection
in HIV-2 disease. Post-mortem studies indicate that it does
occur.32 Progressive multifocal leuko-encephalopathy,
caused by the JC virus, has not been reported. There is no
association with cerebral malaria, which is mainly a disease
of young children in West Africa, nor has HIV-2 infection
been documented in patients with African trypanosomiasis.
Conclusions
The absence of hard data on the neuropathology of HIV-2
infection is due to its low prevalence worldwide, compared
with HIV-1, together with the absence of diagnostic facilities
in west Africa, which is the major endemic region.
Nevertheless there is good evidence that it produces a
similar pattern of disease to HIV-1, even if it is less
pathogenic; it has neurotropic effects and causes disease by
direct invasion of the nervous system and
immunosuppression that allows opportunistic infections.
South African patients with HIV-2 disease will probably at
some time have lived in the former Portuguese colonies of
Angola and Mozambique.'"
I thank Lynne Rolfe for typing the manuscript.
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